Pfizer and Merck, ostensibly beleaguered drugmakers, have seen their shares battered despite reporting strong earnings.

Wall Street rebounds as tech stocks surge, with the S&P 500 up 0.5% amid easing trade tensions and strong corporate earnings.

Merck reported Q4 sales of $15.62 billion, surpassing estimates, with EPS at $1.72. Goldman Sachs remains bullish despite a ...

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.

Merck & Co.'s heavy reliance on its cancer drug Keytruda, which accounts for nearly half of the company's revenue, is raising investor concerns as the drug's patent expiration approaches in 2028, The ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Merck (NYSE: MRK) recently released its Q4 results, with revenues and earnings exceeding the street estimates.

Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...

The Dow Jones Industrial Average is down Wednesday morning with shares of UnitedHealth and Merck seeing the biggest drops for the price-weighted average.

As Moderna maps out a more cautious future amid lower-than-expected sales of its current products, the company is bolstering ...

Merck & Co.’s blockbuster vaccine Gardasil has had a roller-coaster ride in China. A post-Covid surge in demand for the ...

Gossamer Bio Inc. has released new data showing its inhaled kinase inhibitor, seralutinib, has long-lasting effects on ...